Advanced Solid TumorPhase 1NCT06598800
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
A Phase 1 study testing Drug: BG-T187 and Other Therapeutic Agents in people with Advanced Solid Tumor, run by BeOne Medicines at 34 sites in 4 countries.
Trial summary
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Solid Tumor
- What is being tested?
- Drug: BG-T187 and Other Therapeutic Agents
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 153 participants
- Where
- 34 sitesin 4 countries
- Study dates
- 18 Oct 2024to 30 Sep 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.
- Participants must be ≥ 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place.
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
- Participants with selected histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have been previously treated, including but not limited to non-small cell lung cancer (NSCLC), colorectal cancer (CRC).
- ≥ 1 measurable or nonmeasurable lesion as assessed by RECIST v1.1. for Phase 1a Part A; ≥ 1 measurable lesion per RECIST v1.1. for Phase 1a Part B and Phase 1b.
- Adequate organ function.
Who cannot join
- Prior severe allergic reactions or hypersensitivity to the active ingredient and excipients of BG-T187 or other monoclonal antibodies.
- Spinal cord compression, active leptomeningeal disease, or uncontrolled, untreated brain metastasis.
- Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
- History of interstitial lung disease (ILD) or noninfectious pneumonitis requiring steroids or other immune suppressive agents ≤ 2 years before the first dose of the study drug, or with current ILD/noninfectious pneumonitis, or where suspected ILD/noninfectious pneumonitis cannot be ruled out by imaging during screening.
- Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence ≤14 days after intervention).
- Active hepatitis C.
- Infection (including tuberculosis infection, or other) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy ≤ 14 days before the first dose of study drug(s).
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Trial locations and contacts
34 sites in 4 countries. Contact the study team or a site near you to ask about taking part.
Study Director contact
34 sites in 4 countries
China19 sites, 19 recruiting
- Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021
- Recruiting
Hunan Cancer Hospital
Changsha, Hunan, 410013
- Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030
- Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, 350014
- Recruiting
Fujian Medical University Union Hospitalqishan Branch
Fuzhou, Fujian, 350108
- Recruiting
The Sixth Affiliated Hospital, Sun Yat Sen University
Guangzhou, Guangdong, 510655
- Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022
- Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicinezhijiang Branch
Hangzhou, Zhejiang, 310024
- Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000
- Recruiting
Linyi Peoples Hospital
Linyi, Shandong, 276000
- Recruiting
The First Affiliated Hospital of Nanchang University Branch Xianghu
Nanchang, Jiangxi, 332000
- Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021
- Recruiting
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, 200032
- Recruiting
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042
- Recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011
- Recruiting
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013
- Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060
- Recruiting
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430030
- Recruiting
Hubei Cancer Hospital
Wuhan, Hubei, 430079
South Korea7 sites, 7 recruiting
- Recruiting
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, 06351
- Recruiting
The Catholic University of Korea, St Vincents Hospital
PaldalGu SuwonSi, Gyeonggi-do, 16247
- Recruiting
The Catholic University of Korea, Seoul St Marys Hospital
SeochoGu, Seoul Teugbyeolsi, 06591
- Recruiting
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, 03722
- Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620
- Recruiting
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, 03080
- Recruiting
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi, 05505
United States4 sites, 4 recruiting
- Recruiting
Next Oncology Virginia
Fairfax, Virginia, 22031
- Recruiting
Hackensack University Medical Center
Hackensack, New Jersey, 07601-1915
- Recruiting
The University of Texas Md Anderson Cancer Center
Houston, Texas, 77030-4009
- Recruiting
Washington University, St Louis, Division of Oncology
Madison, Wisconsin, 53708-8056
Australia4 sites, 4 recruiting
- Recruiting
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, NSW 2148
- Recruiting
Cabrini Hospital Malvern
Malvern, Victoria, VIC 3144
- Recruiting
Linear Clinical Research
Nedlands, Western Australia, WA 6009
- Recruiting
Macquarie University
North Ryde, New South Wales, NSW 2109
About this study
Official title: A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.
Read the detailed description
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
- Conditions
- Advanced Solid Tumor
- Being tested
- Drug: BG-T187, Other Therapeutic Agents
- Keywords
- Advanced Solid Tumors, First-in-human, BG-T187, EGFR, c-MET
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Drug: BG-T187Drug
administered subcutaneously
Other Therapeutic AgentsDrug
administered intravenously
| Study group | Role | What they receive |
|---|---|---|
| Phase 1a: Part A: Monotherapy Dose Escalation with Intravenous Administration | Experimental | Sequential cohorts of increasing dose levels of BG-T187 will be evaluated as monotherapy. Receives: Drug: Drug: BG-T187 |
| Phase 1a: Part B: Monotherapy Dose Escalation with Subcutaneous Administration | Experimental | Sequential cohorts of increasing dose levels of BG-T187 will be evaluated as monotherapy. Receives: Drug: Drug: BG-T187 |
| Phase 1a Part C: Safety Expansion | Experimental | BG-T187 dose levels that have been determined to be safe and tolerable in Part B will be investigated. Receives: Drug: Drug: BG-T187 |
| Phase 1b: Monotherapy Dose Expansion with Subcutaneous Administration | Experimental | Participants will receive BG-T187 monotherapy at the recommended dose(s) for expansion (RDFE) determined in Phase 1a. Receives: Drug: Drug: BG-T187 |
| Phase 1b: Combination Therapy: BG-T187 + Other Therapeutic Agents | Experimental | Participants will receive BG-T187 in combination with Other Therapeutic Agents. Receives: Drug: Drug: BG-T187; Drug: Other Therapeutic Agents |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of participants with AEs including serious adverse events (SAEs), defined as any unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease temporally associated with the use of study drugs, whether considered related to study drugs or not as graded by the National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI CTCAE) V5.0/American Society for Transplantation and Cellular Therapy (ASTCT) for cytokine release syndrome [CRS] and immune effector cell associated neurotoxicity syndrome [ICANS]); and adverse events meeting protocol-defined dose-limiting toxicity (DLT) criteria
Measured: Approximately 2 years
Phase 1a: Maximum Administered Dose (MAD) or Maximum Tolerated Dose (MTD) of BG-T187
MTD or MAD is defined as the highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30% or the highest dose administered, respectively.
Measured: Approximately 2 years
Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BG-T187
RDFE(s) is determined based on the MAD or MTD, taking into consideration the long-term tolerability, pharmacokinetics (PK), preliminary antitumor activity, and any other relevant data, as available
Measured: Approximately 2 years
Phase 1b: Overall Response Rate (ORR)
ORR is defined as the percentage of participants with confirmed best overall response (BOR) complete response (CR) or partial response (PR) as determined by investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measured: Approximately 2 years
Phase 1b: Recommended Phase 2 dose (RP2D) of BG-T187 alone and in combination with other therapeutic agents
R2PD is determined based on safety, tolerability, PK, preliminary antitumor activity, and other relevant data, as available
Measured: Approximately 2 years
Secondary outcomes (9)
Phase 1a: ORR
ORR is defined as the percentage of participants with confirmed BOR, CR or PR as determined by investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measured: Approximately 2 years
Phase 1a and 1b: Duration of Response (DOR)
DOR is defined as the time from the first objective response until the first documentation of disease progression after treatment initiation or death, whichever comes first, as determined by investigators per RECIST v1.1
Measured: Approximately 2 years
Phase 1a and 1b: Disease Control Rate (DCR)
DCR is defined as the percentage of participants with the BOR of confirmed CR, PR, or stable disease, as determined by investigators per RECIST v1.1
Measured: Approximately 2 years
Phase 1b: Progression Free Survival (PFS)
PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death due to any cause, whichever occurs first, as determined by investigators per RECIST v1.1
Measured: Approximately 2 years
Phase 1a: Maximum observed plasma concentration (Cmax) of BG-T187
Measured: From Cycle 1 to Cycle 3 (each cycle is 28 days)
Phase 1a: Area Under the Plasma Concentration-time Curve (AUC) of BG-T187
Measured: From Cycle 1 to Cycle 3 (each cycle is 28 days)
Phase 1a: Terminal Half-Life (t1/2) of BG-T187
Measured: From Cycle 1 to Cycle 3 (each cycle is 28 days)
Phase 1a: Time to maximum plasma concentration (Tmax) of BG-T187
Measured: From Cycle 1 to Cycle 3 (each cycle is 28 days)
Phase 1b: Number of Participants with AEs and SAEs
Number of participants with AEs including serious adverse events (SAEs), defined as any unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease temporally associated with the use of study drugs, whether considered related to study drugs or not as graded by the National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI CTCAE) V5.0/American Society for Transplantation and Cellular Therapy (ASTCT)
Measured: Approximately 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start18 Oct 2024
- Primary completion30 Sep 2028 (estimated)
- Study completion30 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Solid TumorStudies of the same condition, open and under way.
- More trials run by BeOne MedicinesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 153 participants (estimated)
Sponsor and investigators
- Lead sponsor
- BeOne Medicines
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Study Director, Study director, BeOne Medicines
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06598800
- Sponsor's protocol ID
- BG-T187-101
- Other IDs
- 2024-514944-10-00
- Status last verified
- Sep 2026
- First submitted
- 12 Sep 2024
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
- ClinicalTrials.gov ID
- NCT06598800
- Acronym / sponsor ID
- BG-T187-101
- Conditions
- Advanced Solid Tumor
- Keywords
- Advanced Solid Tumors, First-in-human, BG-T187, EGFR, c-MET
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 153 participants (estimated)
- Lead sponsor
- BeOne MedicinesIndustry (pharma, biotech, devices)
- Study start
- 18 Oct 2024 (actual)
- Primary completion
- 30 Sep 2028 (estimated)
- Study completion
- 30 Sep 2028 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.
Detailed description
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Phase 1a: Part A: Monotherapy Dose Escalation with Intravenous Administration | Experimental | Drug: Drug: BG-T187Sequential cohorts of increasing dose levels of BG-T187 will be evaluated as monotherapy. |
| Phase 1a: Part B: Monotherapy Dose Escalation with Subcutaneous Administration | Experimental | Drug: Drug: BG-T187Sequential cohorts of increasing dose levels of BG-T187 will be evaluated as monotherapy. |
| Phase 1a Part C: Safety Expansion | Experimental | Drug: Drug: BG-T187BG-T187 dose levels that have been determined to be safe and tolerable in Part B will be investigated. |
| Phase 1b: Monotherapy Dose Expansion with Subcutaneous Administration | Experimental | Drug: Drug: BG-T187Participants will receive BG-T187 monotherapy at the recommended dose(s) for expansion (RDFE) determined in Phase 1a. |
| Phase 1b: Combination Therapy: BG-T187 + Other Therapeutic Agents | Experimental | Drug: Drug: BG-T187, Drug: Other Therapeutic AgentsParticipants will receive BG-T187 in combination with Other Therapeutic Agents. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.
- Participants must be ≥ 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place.
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
- Participants with selected histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have been previously treated, including but not limited to non-small cell lung cancer (NSCLC), colorectal cancer (CRC).
- ≥ 1 measurable or nonmeasurable lesion as assessed by RECIST v1.1. for Phase 1a Part A; ≥ 1 measurable lesion per RECIST v1.1. for Phase 1a Part B and Phase 1b.
Key exclusion criteria (8 listed)
- Prior severe allergic reactions or hypersensitivity to the active ingredient and excipients of BG-T187 or other monoclonal antibodies.
- Spinal cord compression, active leptomeningeal disease, or uncontrolled, untreated brain metastasis.
- Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
- History of interstitial lung disease (ILD) or noninfectious pneumonitis requiring steroids or other immune suppressive agents ≤ 2 years before the first dose of the study drug, or with current ILD/noninfectious pneumonitis, or where suspected ILD/noninfectious pneumonitis cannot be ruled out by imaging during screening.
- Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence ≤14 days after intervention).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Drug: BG-T187administered subcutaneously | Drug | Phase 1a Part C: Safety Expansion, Phase 1a: Part A: Monotherapy Dose Escalation with Intravenous Administration, Phase 1a: Part B: Monotherapy Dose Escalation with Subcutaneous Administration, Phase 1b: Combination Therapy: BG-T187 + Other Therapeutic Agents, Phase 1b: Monotherapy Dose Expansion with Subcutaneous Administration |
| Other Therapeutic Agentsadministered intravenously | Drug | Phase 1b: Combination Therapy: BG-T187 + Other Therapeutic Agents |
Primary outcome
Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Approximately 2 years
Number of participants with AEs including serious adverse events (SAEs), defined as any unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease temporally associated with the use of study drugs, whether considered related to study drugs or not as graded by the National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI CTCAE) V5.0/American Society for Transplantation and Cellular Therapy (ASTCT) for cytokine release syndrome [CRS] and immune effector cell associated neurotoxicity syndrome [ICANS]); and adverse events meeting protocol-defined dose-limiting toxicity (DLT) criteria
Phase 1a: Maximum Administered Dose (MAD) or Maximum Tolerated Dose (MTD) of BG-T187
Time frame: Approximately 2 years
MTD or MAD is defined as the highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30% or the highest dose administered, respectively.
Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BG-T187
Time frame: Approximately 2 years
RDFE(s) is determined based on the MAD or MTD, taking into consideration the long-term tolerability, pharmacokinetics (PK), preliminary antitumor activity, and any other relevant data, as available
Phase 1b: Overall Response Rate (ORR)
Time frame: Approximately 2 years
ORR is defined as the percentage of participants with confirmed best overall response (BOR) complete response (CR) or partial response (PR) as determined by investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Phase 1b: Recommended Phase 2 dose (RP2D) of BG-T187 alone and in combination with other therapeutic agents
Time frame: Approximately 2 years
R2PD is determined based on safety, tolerability, PK, preliminary antitumor activity, and other relevant data, as available
9 secondary outcomes
Phase 1a: ORR
Time frame: Approximately 2 years
Phase 1a and 1b: Duration of Response (DOR)
Time frame: Approximately 2 years
Phase 1a and 1b: Disease Control Rate (DCR)
Time frame: Approximately 2 years
Phase 1b: Progression Free Survival (PFS)
Time frame: Approximately 2 years
Phase 1a: Maximum observed plasma concentration (Cmax) of BG-T187
Time frame: From Cycle 1 to Cycle 3 (each cycle is 28 days)
Phase 1a: Area Under the Plasma Concentration-time Curve (AUC) of BG-T187
Time frame: From Cycle 1 to Cycle 3 (each cycle is 28 days)
Phase 1a: Terminal Half-Life (t1/2) of BG-T187
Time frame: From Cycle 1 to Cycle 3 (each cycle is 28 days)
Phase 1a: Time to maximum plasma concentration (Tmax) of BG-T187
Time frame: From Cycle 1 to Cycle 3 (each cycle is 28 days)
Phase 1b: Number of Participants with AEs and SAEs
Time frame: Approximately 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: Yes. BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Related trials for Advanced Solid Tumor
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
RecruitingPhase 1/2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Study Director contact
Study Director study director
BeOne Medicines
34 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Drug: BG-T187 and Other Therapeutic Agents in people with Advanced Solid Tumor, run by BeOne Medicines at 34 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 34 sites in China, South Korea, United States, Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Study Director (1.877.828.5568, clinicaltrials@beonemed.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) (time frame: Approximately 2 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.